Uncategorized
Insmed moves closer to $6B opportunity as PAH drug shows long-term durability
Insmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements through one year of follow-up.